Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 19% Improvement Relative Risk HCQ  Rivera-Izquierdo et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 238 patients in Spain No significant difference in mortality c19hcq.org Rivera-Izquierdo et al., Medicina Clín.., Jul 2020 Favors HCQ Favors control

Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad

Rivera-Izquierdo et al., Medicina Clínica, doi:10.1016/j.medcli.2020.06.025
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
Retrospective 238 hospitalized patients in Spain showing lower mortality with HCQ, adjusted hazard ratio aHR 0.81 [0.24-2.76].
Although the 19% lower mortality is not statistically significant, it is consistent with the significant 25% lower mortality [20‑29%] from meta analysis of the 250 mortality results to date.
risk of death, 19.0% lower, RR 0.81, p = 0.75, treatment 215, control 23.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rivera-Izquierdo et al., 9 Jul 2020, retrospective, Spain, peer-reviewed, 21 authors.
This PaperHCQAll
Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad
Mario Rivera-Izquierdo, María Del Carmen Valero-Ubierna, Juan Luis R-Delamo, Miguel Ángel Fernández-García, Silvia Martínez-Diz, Arezu Tahery-Mahmoud, Marta Rodríguez-Camacho, Ana Belén Gámiz-Molina, Nicolás Barba-Gyengo, Pablo Gámez-Baeza, Celia Cabrero-Rodríguez, Pedro Antonio Guirado-Ruiz, Divina Tatiana Martín-Romero, Antonio Jesús Láinez-Ramos-Bossini, María Rosa Sánchez-Pérez, José Mancera-Romero, Miguel García-Martín, Luis Miguel Martín-Delosreyes, Virginia Martínez-Ruiz, Eladio Jiménez-Mejías
Medicina Clínica, doi:10.1016/j.medcli.2020.06.025
Antecedentes y objetivo: En los últimos meses se han realizado grandes esfuerzos para evaluar las terapias más eficaces en el manejo de pacientes con COVID-19. Actualmente ninguna combinación ha demostrado de manera consistente una relación clara con la mortalidad. Nuestro objetivo fue valorar el patrón de asociaciones observado entre los distintos tratamientos intrahospitalarios administrados a 238 pacientes ingresados por COVID-19 y la mortalidad. Materiales y métodos: Se analizaron las historias clínicas electrónicas de aquellos pacientes dados de alta o que fallecieron por COVID-19 entre el 16 de marzo y el 10 de abril de 2020 en el Hospital Universitario San Cecilio (Granada, Espa ña). Se obtuvo información sobre sexo, edad, comorbilidades al ingreso, parámetros clínicos, analíticos, pruebas de imagen y tratamientos empíricos empleados. La variable de desenlace fue la mortalidad intrahospitalaria. Para estimar las asociaciones entre los diferentes tratamientos y el riesgo de mortalidad se estimaron, mediante modelos de regresión de Cox, hazard ratio ajustadas por edad, sexo, patologías previas y gravedad al ingreso. Resultados: La combinación de fármacos más frecuentemente empleada fue la formada por heparina de bajo peso molecular (HBPM), hidroxicloroquina y ritonavir/lopinavir. Ninguno de los tratamientos utilizados mostró una asociación independiente con la mortalidad. Los fármacos que mostraron una asociación inversa de mayor magnitud fueron el tocilizumab y los corticoides. Conclusiones: El patrón se asociaciones obtenido es consistente con lo reportado en la bibliografía. Parece oportuno dise ñar ensayos aleatorizados que valoren el posible efecto protector de los corticoides y el tocilizumab sobre el riesgo de muerte en algunos subgrupos de pacientes hospitalizados por COVID-19.
References
Ahsan, Javed, Bratty, Alhazmi, Najmi, Treatment of SARS-CoV-2: how far have we reached?, Drug Discov Ther, doi:10.5582/ddt.2020.03008
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of COVID-19 -Preliminary report, N Engl J Med, doi:10.1016/j.ijantimicag.2020.105955
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104786
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, doi:10.1093/cid/ciaa237
Chen, Liu, Liu, Liu, Xu et al., A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19, doi:10.1016/j.jiph.2020.03.019
Choy, Wong, Kaewpreedee, Sia, Chen et al., Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104786
Da, Xue, Yi, Ban, None
Dong, Hu, Gao, Discovering drugs to treat coronavirus disease, doi:10.18433/jpps31002
Du, Chen, Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clin Pharmacol Ther, doi:10.1056/NEJMoa2001282
El-Aziz, Stockand, Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) -an update on the status, Infect Genet Evol, doi:10.3760/cma.j.issn.1001-0939.2020.0002
Esposito, Noviello, Pagliano, Update on treatment of COVID-19: ongoing studies between promising and disappointing results, Infez Med, doi:10.1001/jama.2020.6019
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.antiviral.2020.104787
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2012410
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1016/j.jmii.2020.02.012
Harapan, Itoh, Yufika, Winardi, Keam et al., Coronavirus disease 2019 (COVID-19): a literature review, J Infect Public Health, doi:10.3906/sag-2004-145
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S1473-3099(20)30132-8
Lai, Liu, Wang, Wang, Hsueh et al., Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths, J Microbiol Immunol Infect, doi:10.1016/S0140-6736(20)31022-9
Li, Wang, Xu, Cao, Potential antiviral therapeutics for 2019 Novel Coronavirus, doi:10.5582/ddt.2020.03008
Luo, Liu, Qiu, Liu, Liu et al., Tocilizumab treatment in COVID-19: a single center experience, J Med Virol, doi:10.1016/S0140-6736(20)30183-5
Molina, Delaugerre, Goff, Lima, Ponscarme et al., No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Med Mal Infect, doi:10.1056/NEJMoa2012410
Nicola, Neill, Sohrabi, Khan, Agha et al., Evidence based management guideline for the COVID-19 pandemic -Review article, Int J Surg, doi:10.1016/j.meegid.2020.104327
Rabby, Current drugs with potential for treatment of COVID-19: a literature review, J Pharm Pharm Sci, doi:10.1016/j.ijsu.2020.04.001
Richardson, Griffin, Tucker, Smith, Oechsle et al., Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, Lancet, doi:10.1002/jmv.25801
Rubio, Del Castillo, De La Hera Fernández, Arrabal, Ruiz et al., Eficacia de los pulsos de corticoides en pacientes con síndrome de liberación de citocinas inducido por infección por SARS-CoV-2, Med Clin (Barc), doi:10.3332/ecancer.2020.1023
Russell, Millar, Baillie, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet, doi:10.1073/pnas.2005615117
Russell, Moss, Rigg, Van Hemelrijck, COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience, doi:10.1016/S0140-6736(20)30317-2
S ¸ Ims ¸ Ek Yavuz, Ünal, Antiviral treatment of COVID-19, Turk J Med Sci, doi:10.1016/j.ijantimicag.2020.105949
Saghazadeh, Rezaei, Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: anti-antibodies, immunoglobulins, and corticosteroids, Int Immunopharmacol, doi:10.1016/j.intimp.2020.106560
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for Coronavirus Disease, doi:10.5582/ddt.2020.01012
Stebbing, Phelan, Griffin, Tucker, Oechsle et al., COVID-19: combining antiviral and anti-inflammatory treatments, Lancet Infect Dis, doi:10.1016/j.medmal.2020.03.006
Toniati, Piva, Cattalini, Garrafa, Regola et al., Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy, Autoimmun Rev, doi:10.1016/j.intimp.2020.106560
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1002/cpt.1844
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1056/NEJMoa2007764
Wynants, Van Calster, Collins, Riley, Heinze et al., Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal, BMJ, doi:10.1016/j.autrev.2020.102568
Xu, Han, Li, Sun, Wang et al., Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci, doi:10.1016/S0140-6736(20)30304-4
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
Zhai, Ding, Wu, Long, Zhong et al., The epidemiology, diagnosis and treatment of COVID-19, Int J Antimicrob Agents, doi:10.1016/j.medcli.2020.04.018
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit